Concepedia

Clinical impact of BAALC expression in high-risk acute promyelocytic leukemia

Antonio R. Lucena‐Araujo, Diego A. Pereira‐Martins, Luisa C A Koury, Pedro L. Franca‐Neto, Juan Luiz Coelho‐Silva, Virgínia Mara de Deus Wagatsuma, Raul Antônio Morais Melo, Rosane Bittencourt, Kátia Bórgia Barbosa Pagnano, Ricardo Pasqüini,

Blood Advances · 2017 · 11 citations · 35 references

DOIFull text

Open access

Concepts

Abstract

Key Points BAALC expression is significantly lower in APL compared with other subsets of AML and healthy volunteers. BAALC overexpression can independently predict shorter DFS in patients with high-risk disease.

References

35

Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer

Reiki Nishimura, Tomofumi Osako, Yasuyuki Nishiyama et al. · Oncology · 2013 · 13.2K citations · Full text

, , +17

Evaluating the Yield of Medical Tests

Frank E. Harrell · JAMA · 1982 · 3.4K citations

, , +15

Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia

Francesco Lo‐Coco, Giuseppe Avvisati, Marco Vignetti et al. · New England Journal of Medicine · 2013 · 1.6K citations · Full text

, , +17

Survival Model Predictive Accuracy and ROC Curves

Patrick J. Heagerty, Yingye Zheng · Biometrics · 2005 · 1.5K citations

, , +16

Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.

Clara D. Bloomfield, David Lawrence, John C. Byrd et al. · PubMed · 1998 · 696 citations

, , +15